Networking in rare cancers: What was done, what's next
Publication date: January 2019Source: European Journal of Surgical Oncology, Volume 45, Issue 1Author(s): Anna Maria Frezza, Annalisa Trama, Jean-Yves Blay, Paolo G. CasaliAbstractRare cancers represent approximately one fourth of all cancers. Despite being a heterogeneous group of diseases, they share similar problems including lack of expertise, issues in quality of care, discrepancies in outcome and limitations in research. Traditionally, centralization of rare cancer patients to dedicated reference centres has been recommended to ensure expertise, multidisciplinarity and access to innovation. However, centralization entails health migration, rationing of resources and a potential failure in routine care. By ensuring appropriate care to all patients regardless the point of access, networking seems the most appropriate answer to the problem of rare cancers. The launch of the Joint Action on Rare Cancers as well as the recent establishment of the European Reference Networks represent for the first time a concrete opportunity to make networking a reality and ultimately reduce disparities and improve outcome in these diseases.
Publication date: Available online 20 November 2019Source: Journal of Advanced ResearchAuthor(s): Sohail Mumtaz, Pradeep Bhartiya, Neha Kaushik, Manish Adhikari, Pradeep Lamichhane, Su-Jae Lee, Nagendra Kumar Kaushik, Eun Ha ChoiAbstractOver the past few decades, microwave (MW) radiation has been widely used, and its biological effects have been extensively investigated. However, the effect of MW radiation on human skin biology is not well understood. We study the effects of pulsed high-power microwaves (HPMs) on melanoma (G361 and SK-Mel-31) and normal human dermal fibroblast (NHDF) cells. A pulsed power generator (Chundo...
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 16 December 2019, highlighting Roche data presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, from 10th - 14th December.
Journal of Medicinal Food, Ahead of Print.
CONCLUSIONS Our data demonstrate an oncogenic role of miR-652 in uveal melanoma, showing that miR-652 may be a useful biomarker for prediction of prognosis for patients with uveal melanoma. PMID: 31740654 [PubMed - in process]
This study identified correlates of good screening performance for three common cancers, while weighing them against the backdrop of existing knowledge, to enable policy makers and healthcare providers focus appropriately to close the gaps that exist in cancer screening in our locale. Study design: Cross-sectional design. Setting: Tertiary health facility. Participants: Workers at Delta State University Teaching Hospital, Nigeria. Results: Females had significantly better knowledge of cervical cancer, p
Employing multiple artificial intelligence (AI) algorithms to attack a task...Read more on AuntMinnie.comRelated Reading: Practical Considerations of AI: Part 6 -- Ready, fire, aim Deep-learning algorithm bolsters lung cancer detection AI needs robust clinical evaluation in healthcare Deep-learning model characterizes PET/CT findings Can AI find brain hemorrhage as well as radiologists?
Future Oncology, Ahead of Print.
Future Oncology, Ahead of Print.
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Publication date: Available online 20 November 2019Source: Materials Science and Engineering: CAuthor(s): P. Maheswari, S. Harish, M. Navaneethan, C. Muthamizhchelvan, S. Ponnusamy, Y. HayakawaAbstractTitanium dioxide nanoparticles exhibit good anticancer and antibacterial activities. They are known to be environmentally friendly and stable, less toxic and excellent biocompatibility nature. Due to these properties, they are well suited for biological applications particularly in biomedical applications such as drug delivery and cancer therapy. In this paper Pure TiO2 nanoparticles modified with Withania somnifera (Ashwagan...